Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Proof of Principle Program - Phase II

McGill University

$300,000.00

Evaluation of novel flavonoids in models of hematological cancer

FY 2011-12

Summary
Multiple myeloma is the second most prevalent blood cancer. According to the 2011 Canadian Cancer Statistics report there are approximately 7,000 Canadians living with myeloma. It is estimated that in 2011, 2,300 new cases of myeloma will be diagnosed in Canada, and there will be 1,370 myeloma deaths. Multiple myeloma patients treated with Velcade have approximately a six-month overall survival benefit. However, despite its impressive activity, most patients either fail to respond or develop resistance to Velcade treatment. In addition, this activity can be blocked by certain dietary constituents and Velcade has dose-limiting side-effects including neurotoxicity. We have taken advantage of many years of extensive scientific studies that have demonstrated the benefits of green tea consumption in preventing cancer. We have developed a procedure to chemically synthesize the most active ingredient in green tea that inhibits tumor growth. This compound is abbreviated as EGCG. We have developed modifications of EGCG, called prodrugs, that are more potent in reducing tumor growth than EGCG. We have discovered that one of our prodrugs, called FPE001, affects the same cellular pathway that is also affected by Velcade. However, unlike Velcade, FPE001 also affects another pathway that becomes activated in many cancers. Based on our initial studies, we expect that FPE001 will be safer to use than Velcade and will overcome many of Velcade's limitations. We also expect that FPE001 will be effective in other blood cancers such as chronic lymphocytic leukemia (CLL). So far, Velcade has not shown benefit in CLL patients. CLL is the most common type of leukemia in adults and 2,400 Canadians were expected to be diagnosed in 2010. Our research proposal will complete the proof-of-principle for using FPE001 in blood cancers and directly demonstrate its advantages over Velcade. The proposed experiments will help us to move FPE001 closer to clinical use in patients.
Program
Proof of Principle Program - Phase II
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
240602
Name
Chan Tak Hang
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cognovie Inc. (Toronto, Ontario); MSBi Valorisation (Quebec)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Evaluation of novel flavonoids in models of hematological cancer
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase II
Keyworddelim
Apoptosis; Cell Proliferation; Chronic Lymphocytic Leukemia; Egcg; Flavonoid; Green Tea; Multiple Myeloma; Prodrug; Proteasome; Xenograft
Abstract
Multiple myeloma is the second most prevalent blood cancer. According to the 2011 Canadian Cancer Statistics report there are approximately 7,000 Canadians living with myeloma. It is estimated that in 2011, 2,300 new cases of myeloma will be diagnosed in Canada, and there will be 1,370 myeloma deaths. Multiple myeloma patients treated with Velcade have approximately a six-month overall survival benefit. However, despite its impressive activity, most patients either fail to respond or develop resistance to Velcade treatment. In addition, this activity can be blocked by certain dietary constituents and Velcade has dose-limiting side-effects including neurotoxicity. We have taken advantage of many years of extensive scientific studies that have demonstrated the benefits of green tea consumption in preventing cancer. We have developed a procedure to chemically synthesize the most active ingredient in green tea that inhibits tumor growth. This compound is abbreviated as EGCG. We have developed modifications of EGCG, called prodrugs, that are more potent in reducing tumor growth than EGCG. We have discovered that one of our prodrugs, called FPE001, affects the same cellular pathway that is also affected by Velcade. However, unlike Velcade, FPE001 also affects another pathway that becomes activated in many cancers. Based on our initial studies, we expect that FPE001 will be safer to use than Velcade and will overcome many of Velcade's limitations. We also expect that FPE001 will be effective in other blood cancers such as chronic lymphocytic leukemia (CLL). So far, Velcade has not shown benefit in CLL patients. CLL is the most common type of leukemia in adults and 2,400 Canadians were expected to be diagnosed in 2010. Our research proposal will complete the proof-of-principle for using FPE001 in blood cancers and directly demonstrate its advantages over Velcade. The proposed experiments will help us to move FPE001 closer to clinical use in patients.
Competitiondate
201109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chan, Tak Hang
Approvedterm
1 an 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $300,000~ $0~
McGill University - $300,000 Grant (2011-12) | Canada Spends